Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.42 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.41 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | PLK1 | P53350 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13936448 | 1.00 | GLP1R (0.54) | GLP1RMEN1GAAKMT2AFOLH1 | |
| SCHEMBL22657805 | 0.91 | MEN1 (0.49) | GLP1RMEN1GAAKMT2AFOLH1 | |
| SCHEMBL22657806 | 0.91 | MEN1 (0.49) | GLP1RMEN1GAAKMT2AFOLH1 | |
| SCHEMBL24667758 | 0.89 | GLP1R (0.55) | GLP1RMEN1GAAKMT2AFOLH1 | |
| SCHEMBL13936447 | 0.89 | GLP1R (0.55) | GLP1RMEN1GAAKMT2ATDP1 | |
| SCHEMBL13936445 | 0.89 | GLP1R (0.55) | GLP1RMEN1GAAKMT2ATDP1 | |
| SCHEMBL13936449 | 0.89 | GLP1R (0.55) | GLP1RMEN1GAAKMT2ATDP1 | |
| SCHEMBL13936444 | 0.89 | GLP1R (0.55) | GLP1RMEN1GAAKMT2ATDP1 | |
| SCHEMBL26689262 | 0.87 | GLP1R (0.52) | GLP1RMEN1GAAKMT2AFOLH1 | |
| SCHEMBL26689385 | 0.87 | GLP1R (0.52) | GLP1RMEN1GAAKMT2AFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036353-A1 | Insulin Derivatives Conjugated with Structurally Well Defined Branched Polymers | NOVO NORDISK A/S (DK) | 2009-02-05 | — | — | US | disclosed |
| US-20090036353-A1 | Insulin Derivatives Conjugated with Structurally Well Defined Branched Polymers | NOVO NORDISK A/S (DK) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036353-A1 | Insulin Derivatives Conjugated with Structurally Well Defined Branched Polymers | INSR, IAPP, IGF1R | GLP1R 14/4885MEN1 278/4885GAA 879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.